Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teramed Targets Contraindicated Patients For AAA Stent Graft Market Entry

This article was originally published in The Gray Sheet

Executive Summary

Teramed's kick-off of clinical studies for the Ariba and Tributary abdominal aortic aneurysm stent graft systems indicates both the rapid pace of differentiating innovation in the AAA market and industry's continued interest in minimally invasive surgical solutions to vascular disease.

You may also be interested in...



Guidant, Medtronic AAA Grafts Approved By FDA; Guidant Begins Shipments

Guidant has begun shipping its Ancure endovascular graft for treatment of abdominal aortic aneurysm, and Medtronic is expected to launch its AneuRx AAA device shortly once the company's surgeon training program is finalized. FDA simultaneously approved the two devices on Sept. 28.

Remote Site Visits Will Help US FDA Keep Reviews On Track As Pandemic Constraints Continue

Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.

Execs On The Move: Repro-Med Replaces Its CEO

At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.

UsernamePublicRestriction

Register

MT013291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel